In-market Utilisation of Liraglutide Used for Weight Management in Europe

Novo Nordisk A/S316 enrolled

Overview

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

Study Type

OBSERVATIONAL

Enrollment

316

Conditions

Metabolism and Nutrition Disorder Obesity

Interventions

liraglutideDRUG

Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Initiation of liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg (initiation is defined as no prescription of the same brand within the previous 12 months) * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability of the study Exclusion Criteria: -Patients or physicians who previously participated in interventional studies for liraglutide 3.0 mg / liraglutide 1.2 mg/1.8 mg will not be eligible to participate in the study -For the full study, sites and patients included in the pilot will be excluded

Locations (19)

Novo Nordisk Investigational Site

Bad Nauheim, Germany

Novo Nordisk Investigational Site

Bünde, Germany

Outcomes

Primary Outcomes

Number of patients with BMI above or equal to 30 kg/m^2

Time frame: Less than 6 months before date of first prescription

Number of patients with BMI above or equal to 27kg/m^2 and below 30 kg/m^2 and 1 or more comorbidity

Dysglycaemia (Type 2 Diabetes Mellitus \[T2DM\] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities

Time frame: Less than 6 months before date of first prescription

Number of patients with above or equal to 27 kg/m^2 and below 30 kg/m^2 and no comorbidities

Dysglycaemia (Type 2 Diabetes Mellitus \[T2DM\] or prediabetes), hypertension, dyslipidaemia, obstructive sleep apnoea, and/or other weight-related comorbidities.

Time frame: Less than 6 months before date of first prescription

Number of patients with BMI below 27 kg/m^2

Time frame: Less than 6 months before date of first prescription

Number of patients with BMI not measured

Time frame: Within 6 months before date of the first prescription

Secondary Outcomes

Number of patients with liraglutide 1.2 or 1.8 mg prescriptions with dose information of 3.0 mg per day

Time frame: From date of first prescription until 24 months

Number of patients with liraglutide 1.2 or 1.8 mg prescriptions and indication of weight management

Time frame: From date of first prescription until 24 months

Number of patients with liraglutide 3.0 mg prescriptions who have reached a dose of 3.0 mg

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.